Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Plans $3.6M Public Stock Offering

NEW YORK (GenomeWeb) – Interpace Diagnostics Group announced today that it is planning a $3.6 million public offering of common stock.

The company is offering 1.2 million shares of stock at a public offering price of $3 per share. It expects to receive gross proceeds of approximately $3.6 million, before deducting underwriting discounts and commissions, and other estimated offering expenses. Interpace has also granted the underwriters an over-allotment option to purchase up to an additional 108,000 shares. The offering is expected to close on or about Feb. 8.

Interpace said it intends to use the net proceeds for working capital, to repay debt and other liabilities, and for general corporate purposes.

Maxim Group is acting as sole book-running manager for the offering. Roth Capital Partners is serving as financial advisor.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.